547 related articles for article (PubMed ID: 21821482)
1. [Hypomethylating agents for the treatment of myelodysplastic syndromes].
Itzykson R; Fenaux P
Bull Cancer; 2011 Aug; 98(8):927-34. PubMed ID: 21821482
[TBL] [Abstract][Full Text] [Related]
2. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update.
Joeckel TE; Lübbert M
Semin Hematol; 2012 Oct; 49(4):330-41. PubMed ID: 23079063
[TBL] [Abstract][Full Text] [Related]
3. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.
Yun S; Vincelette ND; Abraham I; Robertson KD; Fernandez-Zapico ME; Patnaik MM
Clin Epigenetics; 2016; 8():68. PubMed ID: 27307795
[TBL] [Abstract][Full Text] [Related]
4. The euphoria of hypomethylating agents in MDS and AML: is it justified?
Sekeres MA
Best Pract Res Clin Haematol; 2013 Sep; 26(3):275-8. PubMed ID: 24309530
[TBL] [Abstract][Full Text] [Related]
5. 5-Azacytidine/Azacitidine.
Müller A; Florek M
Recent Results Cancer Res; 2010; 184():159-70. PubMed ID: 20072837
[TBL] [Abstract][Full Text] [Related]
6. Comparison between decitabine and azacitidine for the treatment of myelodysplastic syndrome: a meta-analysis with 1,392 participants.
Xie M; Jiang Q; Xie Y
Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):22-8. PubMed ID: 25042977
[TBL] [Abstract][Full Text] [Related]
7. Digging deep into "dirty" drugs - modulation of the methylation machinery.
Pleyer L; Greil R
Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
[TBL] [Abstract][Full Text] [Related]
8. Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy?
Lowder JN; Taverna P; Issa JP
Epigenomics; 2015 Oct; 7(7):1083-8. PubMed ID: 26541345
[No Abstract] [Full Text] [Related]
9. Decitabine in the treatment of myelodysplastic syndromes.
Santos FP; Kantarjian H; Garcia-Manero G; Issa JP; Ravandi F
Expert Rev Anticancer Ther; 2010 Jan; 10(1):9-22. PubMed ID: 20014881
[TBL] [Abstract][Full Text] [Related]
10. Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromes.
Steensma DP; Stone RM
Hematol Oncol Clin North Am; 2010 Apr; 24(2):389-406. PubMed ID: 20359633
[TBL] [Abstract][Full Text] [Related]
11. Decitabine.
Gore SD; Jones C; Kirkpatrick P
Nat Rev Drug Discov; 2006 Nov; 5(11):891-2. PubMed ID: 17117522
[No Abstract] [Full Text] [Related]
12. Current status of epigenetic treatment in myelodysplastic syndromes.
Kuendgen A; Lübbert M
Ann Hematol; 2008 Aug; 87(8):601-11. PubMed ID: 18392623
[TBL] [Abstract][Full Text] [Related]
13. DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia.
Flotho C; Sommer S; Lübbert M
Semin Cancer Biol; 2018 Aug; 51():68-79. PubMed ID: 29129488
[TBL] [Abstract][Full Text] [Related]
14. Evidence for Selective Benefit of Sequential Treatment With Hypomethylating Agents in Patients With Myelodysplastic Syndrome.
Apuri S; Al Ali N; Padron E; Lancet JE; List AF; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2017 Apr; 17(4):211-214. PubMed ID: 28185797
[TBL] [Abstract][Full Text] [Related]
15. 5-Azacytidine for the treatment of myelodysplastic syndromes.
Krawczyk J; Keane N; Freeman CL; Swords R; O'Dwyer M; Giles FJ
Expert Opin Pharmacother; 2013 Jun; 14(9):1255-68. PubMed ID: 23621771
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of azacitidine in myelodysplastic syndromes.
Vigil CE; Martin-Santos T; Garcia-Manero G
Drug Des Devel Ther; 2010 Sep; 4():221-9. PubMed ID: 20957213
[TBL] [Abstract][Full Text] [Related]
17. Therapy with azanucleosides for myelodysplastic syndromes.
Quintás-Cardama A; Santos FP; Garcia-Manero G
Nat Rev Clin Oncol; 2010 Aug; 7(8):433-44. PubMed ID: 20551943
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic therapy with decitabine for myelodysplasia and leukemia.
Wijermans P; Lübert M
Future Oncol; 2005 Oct; 1(5):585-91. PubMed ID: 16556035
[TBL] [Abstract][Full Text] [Related]
19. New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomide.
Loiseau C; Ali A; Itzykson R
Exp Hematol; 2015 Aug; 43(8):661-72. PubMed ID: 26123365
[TBL] [Abstract][Full Text] [Related]
20. Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes.
Zeidan AM; Davidoff AJ; Long JB; Hu X; Wang R; Ma X; Gross CP; Abel GA; Huntington SF; Podoltsev NA; Hajime U; Prebet T; Gore SD
Br J Haematol; 2016 Dec; 175(5):829-840. PubMed ID: 27650975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]